|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UBE2V2 |
Gene summary for UBE2V2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UBE2V2 | Gene ID | 7336 |
| Gene name | ubiquitin conjugating enzyme E2 V2 | |
| Gene Alias | DDVIT1 | |
| Cytomap | 8q11.21 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | A0M8W4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7336 | UBE2V2 | GSM4909281 | Human | Breast | IDC | 6.74e-21 | 5.47e-01 | 0.21 |
| 7336 | UBE2V2 | GSM4909282 | Human | Breast | IDC | 2.29e-09 | 3.38e-01 | -0.0288 |
| 7336 | UBE2V2 | GSM4909293 | Human | Breast | IDC | 3.25e-03 | 1.90e-01 | 0.1581 |
| 7336 | UBE2V2 | GSM4909294 | Human | Breast | IDC | 3.54e-10 | 4.06e-01 | 0.2022 |
| 7336 | UBE2V2 | GSM4909296 | Human | Breast | IDC | 5.52e-06 | -2.01e-01 | 0.1524 |
| 7336 | UBE2V2 | GSM4909297 | Human | Breast | IDC | 1.16e-06 | -4.04e-02 | 0.1517 |
| 7336 | UBE2V2 | GSM4909301 | Human | Breast | IDC | 2.10e-04 | -2.02e-01 | 0.1577 |
| 7336 | UBE2V2 | GSM4909311 | Human | Breast | IDC | 1.00e-19 | -2.09e-01 | 0.1534 |
| 7336 | UBE2V2 | GSM4909312 | Human | Breast | IDC | 7.24e-09 | -4.95e-02 | 0.1552 |
| 7336 | UBE2V2 | GSM4909315 | Human | Breast | IDC | 1.61e-10 | 4.69e-01 | 0.21 |
| 7336 | UBE2V2 | GSM4909317 | Human | Breast | IDC | 2.52e-11 | 5.13e-01 | 0.1355 |
| 7336 | UBE2V2 | GSM4909318 | Human | Breast | IDC | 7.32e-05 | 5.37e-01 | 0.2031 |
| 7336 | UBE2V2 | GSM4909319 | Human | Breast | IDC | 3.82e-21 | -1.57e-01 | 0.1563 |
| 7336 | UBE2V2 | GSM4909320 | Human | Breast | IDC | 8.31e-05 | -2.19e-01 | 0.1575 |
| 7336 | UBE2V2 | GSM4909321 | Human | Breast | IDC | 3.46e-08 | -1.40e-01 | 0.1559 |
| 7336 | UBE2V2 | brca1 | Human | Breast | Precancer | 3.42e-08 | 3.13e-01 | -0.0338 |
| 7336 | UBE2V2 | brca2 | Human | Breast | Precancer | 6.99e-07 | 2.84e-01 | -0.024 |
| 7336 | UBE2V2 | brca3 | Human | Breast | Precancer | 1.44e-02 | 2.31e-01 | -0.0263 |
| 7336 | UBE2V2 | NCCBC14 | Human | Breast | DCIS | 2.68e-03 | 5.61e-02 | 0.2021 |
| 7336 | UBE2V2 | NCCBC5 | Human | Breast | DCIS | 1.54e-06 | 6.30e-02 | 0.2046 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00709979 | Breast | Precancer | neuron death | 50/1080 | 361/18723 | 7.75e-09 | 5.70e-07 | 50 |
| GO:00458629 | Breast | Precancer | positive regulation of proteolysis | 51/1080 | 372/18723 | 7.77e-09 | 5.70e-07 | 51 |
| GO:00514029 | Breast | Precancer | neuron apoptotic process | 38/1080 | 246/18723 | 2.68e-08 | 1.75e-06 | 38 |
| GO:00104989 | Breast | Precancer | proteasomal protein catabolic process | 58/1080 | 490/18723 | 1.54e-07 | 8.05e-06 | 58 |
| GO:19033629 | Breast | Precancer | regulation of cellular protein catabolic process | 36/1080 | 255/18723 | 6.03e-07 | 2.55e-05 | 36 |
| GO:19012149 | Breast | Precancer | regulation of neuron death | 41/1080 | 319/18723 | 1.27e-06 | 4.80e-05 | 41 |
| GO:00421769 | Breast | Precancer | regulation of protein catabolic process | 47/1080 | 391/18723 | 1.50e-06 | 5.58e-05 | 47 |
| GO:00435237 | Breast | Precancer | regulation of neuron apoptotic process | 31/1080 | 212/18723 | 1.69e-06 | 6.08e-05 | 31 |
| GO:19030509 | Breast | Precancer | regulation of proteolysis involved in cellular protein catabolic process | 31/1080 | 221/18723 | 4.10e-06 | 1.27e-04 | 31 |
| GO:00611369 | Breast | Precancer | regulation of proteasomal protein catabolic process | 24/1080 | 187/18723 | 1.99e-04 | 3.14e-03 | 24 |
| GO:00431619 | Breast | Precancer | proteasome-mediated ubiquitin-dependent protein catabolic process | 42/1080 | 412/18723 | 2.49e-04 | 3.72e-03 | 42 |
| GO:00098969 | Breast | Precancer | positive regulation of catabolic process | 48/1080 | 492/18723 | 2.62e-04 | 3.84e-03 | 48 |
| GO:00313319 | Breast | Precancer | positive regulation of cellular catabolic process | 43/1080 | 427/18723 | 2.75e-04 | 4.00e-03 | 43 |
| GO:20000589 | Breast | Precancer | regulation of ubiquitin-dependent protein catabolic process | 21/1080 | 164/18723 | 5.00e-04 | 6.53e-03 | 21 |
| GO:19033649 | Breast | Precancer | positive regulation of cellular protein catabolic process | 20/1080 | 155/18723 | 6.10e-04 | 7.67e-03 | 20 |
| GO:00435243 | Breast | Precancer | negative regulation of neuron apoptotic process | 19/1080 | 145/18723 | 6.83e-04 | 8.34e-03 | 19 |
| GO:19012157 | Breast | Precancer | negative regulation of neuron death | 24/1080 | 208/18723 | 9.50e-04 | 1.07e-02 | 24 |
| GO:00510548 | Breast | Precancer | positive regulation of DNA metabolic process | 23/1080 | 201/18723 | 1.34e-03 | 1.41e-02 | 23 |
| GO:19030527 | Breast | Precancer | positive regulation of proteolysis involved in cellular protein catabolic process | 17/1080 | 133/18723 | 1.68e-03 | 1.70e-02 | 17 |
| GO:00457329 | Breast | Precancer | positive regulation of protein catabolic process | 25/1080 | 231/18723 | 1.87e-03 | 1.82e-02 | 25 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0513118 | Breast | Precancer | Shigellosis | 44/684 | 247/8465 | 3.91e-07 | 6.86e-06 | 5.26e-06 | 44 |
| hsa0513119 | Breast | Precancer | Shigellosis | 44/684 | 247/8465 | 3.91e-07 | 6.86e-06 | 5.26e-06 | 44 |
| hsa0513124 | Breast | IDC | Shigellosis | 47/867 | 247/8465 | 1.78e-05 | 2.00e-04 | 1.49e-04 | 47 |
| hsa0513134 | Breast | IDC | Shigellosis | 47/867 | 247/8465 | 1.78e-05 | 2.00e-04 | 1.49e-04 | 47 |
| hsa0513144 | Breast | DCIS | Shigellosis | 46/846 | 247/8465 | 2.06e-05 | 2.38e-04 | 1.75e-04 | 46 |
| hsa0513154 | Breast | DCIS | Shigellosis | 46/846 | 247/8465 | 2.06e-05 | 2.38e-04 | 1.75e-04 | 46 |
| hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa05131310 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa0513122 | Liver | Cirrhotic | Shigellosis | 105/2530 | 247/8465 | 1.31e-05 | 1.21e-04 | 7.48e-05 | 105 |
| hsa0513132 | Liver | Cirrhotic | Shigellosis | 105/2530 | 247/8465 | 1.31e-05 | 1.21e-04 | 7.48e-05 | 105 |
| hsa0513142 | Liver | HCC | Shigellosis | 150/4020 | 247/8465 | 1.53e-05 | 1.04e-04 | 5.81e-05 | 150 |
| hsa0513152 | Liver | HCC | Shigellosis | 150/4020 | 247/8465 | 1.53e-05 | 1.04e-04 | 5.81e-05 | 150 |
| hsa0513130 | Oral cavity | OSCC | Shigellosis | 150/3704 | 247/8465 | 3.96e-08 | 3.12e-07 | 1.59e-07 | 150 |
| hsa05131113 | Oral cavity | OSCC | Shigellosis | 150/3704 | 247/8465 | 3.96e-08 | 3.12e-07 | 1.59e-07 | 150 |
| hsa05131210 | Oral cavity | LP | Shigellosis | 103/2418 | 247/8465 | 4.98e-06 | 4.14e-05 | 2.67e-05 | 103 |
| hsa0513138 | Oral cavity | LP | Shigellosis | 103/2418 | 247/8465 | 4.98e-06 | 4.14e-05 | 2.67e-05 | 103 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UBE2V2 | SNV | Missense_Mutation | c.281N>G | p.Ser94Cys | p.S94C | Q15819 | protein_coding | deleterious(0) | benign(0.017) | TCGA-E2-A1IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| UBE2V2 | SNV | Missense_Mutation | novel | c.223G>C | p.Glu75Gln | p.E75Q | Q15819 | protein_coding | tolerated(0.1) | benign(0.027) | TCGA-ZJ-AAXD-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| UBE2V2 | SNV | Missense_Mutation | c.229N>T | p.Pro77Ser | p.P77S | Q15819 | protein_coding | deleterious(0.03) | possibly_damaging(0.653) | TCGA-CM-5348-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| UBE2V2 | SNV | Missense_Mutation | c.32N>A | p.Arg11His | p.R11H | Q15819 | protein_coding | tolerated(0.11) | benign(0.069) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UBE2V2 | SNV | Missense_Mutation | rs11557776 | c.107N>G | p.Glu36Gly | p.E36G | Q15819 | protein_coding | deleterious(0.02) | possibly_damaging(0.894) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| UBE2V2 | SNV | Missense_Mutation | rs772913593 | c.371N>A | p.Arg124His | p.R124H | Q15819 | protein_coding | tolerated(0.15) | benign(0.009) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| UBE2V2 | SNV | Missense_Mutation | c.124N>G | p.Thr42Ala | p.T42A | Q15819 | protein_coding | tolerated(0.13) | benign(0.011) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| UBE2V2 | SNV | Missense_Mutation | novel | c.143N>A | p.Gly48Asp | p.G48D | Q15819 | protein_coding | deleterious(0.02) | benign(0.39) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| UBE2V2 | SNV | Missense_Mutation | c.32G>A | p.Arg11His | p.R11H | Q15819 | protein_coding | tolerated(0.11) | benign(0.069) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| UBE2V2 | SNV | Missense_Mutation | novel | c.121A>T | p.Met41Leu | p.M41L | Q15819 | protein_coding | tolerated(0.19) | benign(0.007) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |